TEVA 8229 TEVA 8229 Pill - yellow capsule/oblong, 16mm
Pill with imprint TEVA 8229 TEVA 8229 is Yellow, Capsule/Oblong and has been identified as Sunitinib Malate 37.5 mg. It is supplied by Teva Pharmaceuticals USA, Inc.
Sunitinib is used in the treatment of Renal Cell Carcinoma; Pancreatic Cancer; Gastrointestinal Stromal Tumor and belongs to the drug classes multikinase inhibitors, VEGF/VEGFR inhibitors. There is positive evidence of human fetal risk during pregnancy. Sunitinib 37.5 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for TEVA 8229 TEVA 8229
Sunitinib Malate
- Imprint
- TEVA 8229 TEVA 8229
- Strength
- 37.5 mg
- Color
- Yellow
- Size
- 16.00 mm
- Shape
- Capsule/Oblong
- Availability
- Prescription only
- Drug Class
- Multikinase inhibitors, VEGF/VEGFR inhibitors
- Pregnancy Category
- D - Positive evidence of risk
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Teva Pharmaceuticals USA, Inc.
- National Drug Code (NDC)
- 00093-8229
- Inactive Ingredients
-
croscarmellose sodium,
magnesium stearate,
mannitol,
povidone k30,
gelatin,
titanium dioxide,
ferric oxide yellow,
ferrosoferric oxide,
D&C Yellow No. 10 Aluminium Lake,
FD&C Blue No. 1 Aluminium Lake,
FD&C Blue No. 2 Aluminium Lake,
FD&C Red No. 40,
shellac,
propylene glycol
Note: Inactive ingredients may vary.
More about sunitinib
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (35)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
